Effect of prehydration solution on hearing threshold after chemotherapy in patients with head and neck cancers: a retrospective study

• Published in: Journal of yeungnam medical science Vol. 40; no. 2; pp. 164 - 171
• Main Authors: Ahn, Dongbin, Lee, Kyu-Yup, Oh, Eunjung, Oh, Minji, Jung, Boseung, Jung, Da Jung
• Format: Journal Article
• Language: English
• Published: Korea (South) Journal of Yeungnam Medical Science 01.04.2023; Yeungnam University College of Medicine, Yeungnam University Institute Medical Science
• Subjects: cisplatin; drug therapy; hearing; Original; solutions; Drug therapy; Hearing; Cisplatin
• DOI: 10.12701/jyms.2022.00276
• ISSN: 2799-8010

The study aimed to evaluate the effect of prehydration solution on hearing thresholds after cisplatin chemotherapy. In this retrospective cohort study, we reviewed the data of patients who underwent ≥3 courses of cisplatin-based chemotherapy for locally advanced head and neck cancers at a tertiary referral center (n=64). The dextrose solution (DW) group (n=26) received 2 L of normal saline and 1 L of 5% dextrose. The Hartmann solution (HS) group (n=38) received 2 L of normal saline and 1 L of HS. Hearing data were measured 1 day before starting the first course of chemotherapy, and again 20 days after the first, second, and third courses of chemotherapy. The severity of hearing loss was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE). Thresholds at all frequencies after chemotherapy were greater in the DW group than in the HS group. The increase in thresholds in 1 to 4 kHz after the third course of chemotherapy was greater in the DW group than in the HS group. CTCAE grades after the second and third courses of chemotherapy were greater in the DW group than in the HS group. Logistic regression showed that the odds ratio for CTCAE grade 3 or 4 after the third course of chemotherapy in the DW group was 4.84 on univariate analysis. Prehydration using a solution with salt was associated with a decrease in change in hearing thresholds after cisplatin chemotherapy in patients with head and neck cancers.